摘要
目的:探讨重组人生长激素对肝硬化低蛋白血症的临床治疗作用及特点。方法:将36例血清白蛋白含量低于35g/L的肝硬化低蛋白血症患者分为两组,A组给予进口重组人生长激素4IU,肌注,1次/2d,疗程30d,同时给予保肝、对症治疗,B组给予国产重组人生长激素,治疗方案与A组相同,并给予与A组相同的保肝、对症治疗药物。分别于治疗后15、30、60、90d测定各项观察指标。结果:治疗后30d两组患者血清白蛋白含量均上升;治疗后60d两组血清白蛋白水平升至最高点,A组升高更明显;治疗后90dA组仍维持高点水平,且肝功能好转,B组回降。结论:两种重组人生长激素均可明显提高肝硬化低蛋白血症患者血清白蛋白水平,改善肝功能,进口重组人生长激素在中远期疗效方面更有优势。
Objective To investigate the differences between the efficacies of two kinds of recombinant human growth hormone （rhGH） for hypoproteinemia in hepatic cirrhosis. Methods 36 patients with hepatic cirrhosis, whose serum albumin were 〈 35 g/L, were assigned to receive intramuscular injection of 4 IU imported rhGH （group A） or 4 IU local rhGH （group B） once every 2 days for 30 days, and both of the two groups received hepatoprotective and symptomatic treatments. Contents of albumin, ALT, and other items were measured at day 15, 30, 60, and 90 after treatment. Results Serum albumin was increased in both groups at day 30, reached peak at day 60, especially in group A. At day 90, serum albumin remained in high level and hepatic function was improved in group A, and serum albumin was decreased in group B. Conclusion Both of the two kinds of rhGH can increase the level of serum albumin and improve hepatic function of patients with hepatic cirrhosis, but import rhGH has a better long-dated curative effect.
出处
《实用医学杂志》
CAS
北大核心
2009年第14期2343-2345,共3页
The Journal of Practical Medicine
关键词
重组人生长激素
肝硬化
低蛋白血症
Recombinant human growth homone
Liver cirrhosis
Hypoproteinemia
